Cited by 338Nerve injury and regenerationNuclear Receptors and SignalingParkinson's Disease Mechanisms and Treatments

Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons

Open access
Horger, Brian A., Nishimura, Merry C., Armanini, Mark P., Wang, Li-Chong, Poulsen, Kris T., Rosenblad, Carl, Kirik, Deniz, Moffat, Barbara +8 more·1998·The Journal of Neuroscience

Abstract

Glial cell line-derived neurotrophic factor (GDNF) exhibits potent effects on survival and function of midbrain dopaminergic (DA) neurons in a variety of models. Although other growth factors expressed in the vicinity of developing DA neurons have been reported to support survival of DA neurons in vitro, to date none of these factors duplicate the potent and selective actions of GDNF in vivo. We report here that neurturin (NTN), a homolog of GDNF, is expressed in the nigrostriatal system, and that NTN exerts potent effects on survival and function of midbrain DA neurons. Our findings indicate that NTN mRNA is sequentially expressed in the ventral midbrain and striatum during development and that NTN exhibits survival-promoting actions on both developing and mature DA neurons.In vitro, NTN supports survival of embryonic DA neurons, and in vivo, direct injection of NTN into the substantia nigra protects mature DA neurons from cell death induced by 6-OHDA. Furthermore, administration of NTN into the striatum of intact adult animals induces behavioral and biochemical changes associated with functional upregulation of nigral DA neurons. The similarity in potency and efficacy of NTN and GDNF on DA neurons in several paradigms stands in contrast to the differential distribution of the receptor components GDNF Family Receptor α1 (GFRα1) and GFRα2 within the ventral mesencephalon. These results suggest that NTN is an endogenous trophic factor for midbrain DA neurons and point to the possibility that GDNF and NTN may exert redundant trophic influences on nigral DA neurons acting via a receptor complex that includes GFRα1.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.18-13-04929.1998

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • NRTN displays neuroprotection through enhancing dopaminergic neuronal survival and behavioural function in animal models.

    “NRTN displays neuroprotection through enhancing dopaminergic neuronal survival and behavioural function in animal models [73, 74], and adeno-associated virus serotype 2 (AAV-2) vector encoding the human NRTN gene (CERE120) has been developed to potentially provide clinical benefits in Parkinson’s disease [75].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Horger, B. A., Nishimura, M. C., Armanini, M. P., Wang, L.-C., Poulsen, K. T., Rosenblad, C., Kirik, D., Moffat, B., Simmons, L., Johnson, E., Milbrandt, J., Rosenthal, A., Bjorklund, A., Vandlen, R. A., Hynes, M. A., & Phillips, H. S.
Affiliations
Washington University in St. Louis (US)
Venue
The Journal of Neuroscience
Published
1998-07-01
Volume
18
Issue
13
Pages
4929-4937
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2161634584
Cited by
338
References
1
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 10 · 2019: 8 · 2018: 8 · 2017: 6 · 2016: 8 · 2015: 12 · 2014: 9 · 2013: 11 · 2012: 14
FWCI
9.63
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • National Institutes of Health
  • Medical Research Council
  • National Institute on Aging (R01AG013729, R01AG13729, R01 AG13730, R01AG013730)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
neurturin, glial cell line-derived neurotrophic factor, midbrain dopaminergic neurons, neuronal survival, nigrostriatal pathway, substantia nigra, striatum, GFRα2, trophic factors, developmental gene expression
MeSH terms
Animals, Cell Survival, Cells, Cultured, Corpus Striatum, Disease Models, Animal, Dopamine, Nerve Growth Factors, Nerve Tissue Proteins, Neurons, Nucleus Accumbens, Parkinson Disease, Secondary, RNA, Messenger, Substantia Nigra, Sympatholytics, 3,4-Dihydroxyphenylacetic Acid, Oxidopamine, Gene Expression Regulation, Developmental, Neuroprotective Agents, Glial Cell Line-Derived Neurotrophic Factor, Neurturin, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review